Headache & Migraine

Key clinical point: Women vs. men with migraine had a higher frequency of self-reported neck pain and higher prevalence and severity of cutaneous allodynia (CA).

Major finding: Women vs. men showed higher prevalence of self-reported neck pain (73.33% vs. 43.33%; P = .04), CA (P = .001), and 4 times higher risk of having severe CA (P = .007).

Study details: Findings are from a cross-sectional study of 30 men and 30 women with migraine.

Disclosures: The study was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo to NDS Xavier. No other conflicts of interest were reported.

Source: Xavier NDS et al. Pain Med. 2021 Mar 19. doi: 10.1093/pm/pnab106.

Key clinical point: Women vs. men with migraine had a higher frequency of self-reported neck pain and higher prevalence and severity of cutaneous allodynia (CA).

Major finding: Women vs. men showed higher prevalence of self-reported neck pain (73.33% vs. 43.33%; P = .04), CA (P = .001), and 4 times higher risk of having severe CA (P = .007).

Study details: Findings are from a cross-sectional study of 30 men and 30 women with migraine.

Disclosures: The study was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo to NDS Xavier. No other conflicts of interest were reported.

Source: Xavier NDS et al. Pain Med. 2021 Mar 19. doi: 10.1093/pm/pnab106.

Key clinical point: Women vs. men with migraine had a higher frequency of self-reported neck pain and higher prevalence and severity of cutaneous allodynia (CA).

Major finding: Women vs. men showed higher prevalence of self-reported neck pain (73.33% vs. 43.33%; P = .04), CA (P = .001), and 4 times higher risk of having severe CA (P = .007).

Study details: Findings are from a cross-sectional study of 30 men and 30 women with migraine.

Disclosures: The study was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo to NDS Xavier. No other conflicts of interest were reported.

Source: Xavier NDS et al. Pain Med. 2021 Mar 19. doi: 10.1093/pm/pnab106.

Key clinical point: People with migraine may experience a wide range of comorbidities and co-occurring conditions, which should be managed effectively.

Major finding: Patients with vs. without migraine were 3 times more likely to experience insomnia (adjusted odds ratio [aOR], 3.79; 95% confidence interval, [95% CI], 3.6-4.0), depression (aOR, 3.18; 95% CI, 3.0-3.3), anxiety (aOR, 3.18; 95% CI, 3.0-3.3), and gastric ulcer/gastrointestinal bleeding (aOR, 3.11; 95% CI, 2.8-3.5).

Study details: Data come from the prospective, web-based Migraine in America Symptoms and Treatment survey involving adults with (n=15,133) and without migraine (n=77,453).

Disclosures: The study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, USA. The lead author along with others declared receiving grant support and/or honoraria from various sources. S Munjal and P Singh declared being employees while RB Lipton, DC Buse, ML Reed, TJ Schwedt, and DW Dodick reported being consultants at Dr. Reddy’s Laboratories.

Source: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.

Key clinical point: People with migraine may experience a wide range of comorbidities and co-occurring conditions, which should be managed effectively.

Major finding: Patients with vs. without migraine were 3 times more likely to experience insomnia (adjusted odds ratio [aOR], 3.79; 95% confidence interval, [95% CI], 3.6-4.0), depression (aOR, 3.18; 95% CI, 3.0-3.3), anxiety (aOR, 3.18; 95% CI, 3.0-3.3), and gastric ulcer/gastrointestinal bleeding (aOR, 3.11; 95% CI, 2.8-3.5).

Study details: Data come from the prospective, web-based Migraine in America Symptoms and Treatment survey involving adults with (n=15,133) and without migraine (n=77,453).

Disclosures: The study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, USA. The lead author along with others declared receiving grant support and/or honoraria from various sources. S Munjal and P Singh declared being employees while RB Lipton, DC Buse, ML Reed, TJ Schwedt, and DW Dodick reported being consultants at Dr. Reddy’s Laboratories.

Source: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.

Key clinical point: People with migraine may experience a wide range of comorbidities and co-occurring conditions, which should be managed effectively.

Major finding: Patients with vs. without migraine were 3 times more likely to experience insomnia (adjusted odds ratio [aOR], 3.79; 95% confidence interval, [95% CI], 3.6-4.0), depression (aOR, 3.18; 95% CI, 3.0-3.3), anxiety (aOR, 3.18; 95% CI, 3.0-3.3), and gastric ulcer/gastrointestinal bleeding (aOR, 3.11; 95% CI, 2.8-3.5).

Study details: Data come from the prospective, web-based Migraine in America Symptoms and Treatment survey involving adults with (n=15,133) and without migraine (n=77,453).

Disclosures: The study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, USA. The lead author along with others declared receiving grant support and/or honoraria from various sources. S Munjal and P Singh declared being employees while RB Lipton, DC Buse, ML Reed, TJ Schwedt, and DW Dodick reported being consultants at Dr. Reddy’s Laboratories.

Source: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.

Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.

Major finding: Patients reported an average decrease of 10.9 MHDs (P less than .001) after onabot treatment and a further decrease of 5.7 MHDs (P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs (P less than .001) with combined therapy. No serious adverse events were reported.

Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.

Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.

Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093.

Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.

Major finding: Patients reported an average decrease of 10.9 MHDs (P less than .001) after onabot treatment and a further decrease of 5.7 MHDs (P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs (P less than .001) with combined therapy. No serious adverse events were reported.

Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.

Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.

Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093.

Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.

Major finding: Patients reported an average decrease of 10.9 MHDs (P less than .001) after onabot treatment and a further decrease of 5.7 MHDs (P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs (P less than .001) with combined therapy. No serious adverse events were reported.

Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.

Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.

Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093.

Key clinical point: Intravenous eptinezumab demonstrated a favorable safety profile in patients with chronic migraine (CM).

Major finding: Overall, 71.1% of patients experienced 1 or more treatment-emergent adverse events (TEAEs) during the entire 2 years of study duration with majority (95.6%) being mild or moderate. TEAEs leading to drug discontinuation or withdrawal were observed in only 7.8% and 6.3% of patients, respectively. Incidence of serious TEAEs and drug-related AEs was low.

Study details: PREVAIL, an open-label phase 3 trial, included 128 adults with CM who received at least 1 dose of eptinezumab (300 mg) every 12 weeks for up to 8 doses.

Disclosures: This study was funded by H. Lundbeck A/S, Copenhagen, Denmark. D Kudrow reported receiving grant support from, being on advisory board, and/or being speaker for multiple sources. Some of the authors reported being current/former full-time employees at Lundbeck Seattle BioPharmaceuticals or Alder Biopharmaceuticals (CKA Lundbeck Seattle Biopharmaceuticals, Inc).

Source: Kudrow D et al. BMC Neurol. 2021 Mar 19. doi: 10.1186/s12883-021-02123-w.

Key clinical point: Intravenous eptinezumab demonstrated a favorable safety profile in patients with chronic migraine (CM).

Major finding: Overall, 71.1% of patients experienced 1 or more treatment-emergent adverse events (TEAEs) during the entire 2 years of study duration with majority (95.6%) being mild or moderate. TEAEs leading to drug discontinuation or withdrawal were observed in only 7.8% and 6.3% of patients, respectively. Incidence of serious TEAEs and drug-related AEs was low.

Study details: PREVAIL, an open-label phase 3 trial, included 128 adults with CM who received at least 1 dose of eptinezumab (300 mg) every 12 weeks for up to 8 doses.

Disclosures: This study was funded by H. Lundbeck A/S, Copenhagen, Denmark. D Kudrow reported receiving grant support from, being on advisory board, and/or being speaker for multiple sources. Some of the authors reported being current/former full-time employees at Lundbeck Seattle BioPharmaceuticals or Alder Biopharmaceuticals (CKA Lundbeck Seattle Biopharmaceuticals, Inc).

Source: Kudrow D et al. BMC Neurol. 2021 Mar 19. doi: 10.1186/s12883-021-02123-w.

Key clinical point: Intravenous eptinezumab demonstrated a favorable safety profile in patients with chronic migraine (CM).

Major finding: Overall, 71.1% of patients experienced 1 or more treatment-emergent adverse events (TEAEs) during the entire 2 years of study duration with majority (95.6%) being mild or moderate. TEAEs leading to drug discontinuation or withdrawal were observed in only 7.8% and 6.3% of patients, respectively. Incidence of serious TEAEs and drug-related AEs was low.

Study details: PREVAIL, an open-label phase 3 trial, included 128 adults with CM who received at least 1 dose of eptinezumab (300 mg) every 12 weeks for up to 8 doses.

Disclosures: This study was funded by H. Lundbeck A/S, Copenhagen, Denmark. D Kudrow reported receiving grant support from, being on advisory board, and/or being speaker for multiple sources. Some of the authors reported being current/former full-time employees at Lundbeck Seattle BioPharmaceuticals or Alder Biopharmaceuticals (CKA Lundbeck Seattle Biopharmaceuticals, Inc).

Source: Kudrow D et al. BMC Neurol. 2021 Mar 19. doi: 10.1186/s12883-021-02123-w.

Key clinical point: Over half of the patients with migraine who underwent bariatric surgery experienced migraine remission following surgery, with likelihood of remission being higher after Roux-en-Y gastric bypass (RYGB) than after vertical sleeve gastrectomy (VSG).

Major finding: Remission of migraine was observed in 55.4% of patients who underwent surgery. Likelihood of migraine remission was higher with RYGB vs. VSG (adjusted relative rate, 1.11; 95% confidence interval, 1.05-1.17).

Study details: The data come from a retrospective analysis of 1,680 patients with chronic migraine who underwent bariatric surgery (RYGB, n=742; VSG, n=938) between 2010 and 2017.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Nudotor R et al. Obes Surg. 2021 Feb 11. doi: 10.1007/s11695-020-05204-w.

Key clinical point: Over half of the patients with migraine who underwent bariatric surgery experienced migraine remission following surgery, with likelihood of remission being higher after Roux-en-Y gastric bypass (RYGB) than after vertical sleeve gastrectomy (VSG).

Major finding: Remission of migraine was observed in 55.4% of patients who underwent surgery. Likelihood of migraine remission was higher with RYGB vs. VSG (adjusted relative rate, 1.11; 95% confidence interval, 1.05-1.17).

Study details: The data come from a retrospective analysis of 1,680 patients with chronic migraine who underwent bariatric surgery (RYGB, n=742; VSG, n=938) between 2010 and 2017.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Nudotor R et al. Obes Surg. 2021 Feb 11. doi: 10.1007/s11695-020-05204-w.

Key clinical point: Over half of the patients with migraine who underwent bariatric surgery experienced migraine remission following surgery, with likelihood of remission being higher after Roux-en-Y gastric bypass (RYGB) than after vertical sleeve gastrectomy (VSG).

Major finding: Remission of migraine was observed in 55.4% of patients who underwent surgery. Likelihood of migraine remission was higher with RYGB vs. VSG (adjusted relative rate, 1.11; 95% confidence interval, 1.05-1.17).

Study details: The data come from a retrospective analysis of 1,680 patients with chronic migraine who underwent bariatric surgery (RYGB, n=742; VSG, n=938) between 2010 and 2017.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Nudotor R et al. Obes Surg. 2021 Feb 11. doi: 10.1007/s11695-020-05204-w.

Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.

Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).

Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.

Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.

Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2.

Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.

Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).

Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.

Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.

Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2.

Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.

Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).

Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.

Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.

Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2.

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.

Key clinical point: Survey findings from a real-world tertiary headache clinic support the efficacy and safety of ubrogepant for acute treatment of migraine.

Major finding: Complete headache freedom and headache relief at 2 hours after taking ubrogepant for at least 75% of treated attacks were achieved in 19.0% and 47.6% of patients with migraine, respectively. Overall, 31.1% of patients reported being very satisfied with ubrogepant. Rates of adverse events were higher than those observed in clinical trials. However, no severe/serious adverse events were reported.

Study details: The data come from an analysis of questionnaire responses of 106 adult patients with migraine with or without aura treated with ubrogepant at a tertiary headache center.

Disclosures: No source of funding was declared. DW Dodick declared research support/consulting from various sources. AJ Starling declared consulting fees from Alder, Allergan, Amgen, Axsome Therapeutics, and others. Four of the other authors had no disclosures.

Source: Chiang C-C et al. Headache. 2021 Feb 5. doi: 10.1111/head.14062.

Key clinical point: Survey findings from a real-world tertiary headache clinic support the efficacy and safety of ubrogepant for acute treatment of migraine.

Major finding: Complete headache freedom and headache relief at 2 hours after taking ubrogepant for at least 75% of treated attacks were achieved in 19.0% and 47.6% of patients with migraine, respectively. Overall, 31.1% of patients reported being very satisfied with ubrogepant. Rates of adverse events were higher than those observed in clinical trials. However, no severe/serious adverse events were reported.

Study details: The data come from an analysis of questionnaire responses of 106 adult patients with migraine with or without aura treated with ubrogepant at a tertiary headache center.

Disclosures: No source of funding was declared. DW Dodick declared research support/consulting from various sources. AJ Starling declared consulting fees from Alder, Allergan, Amgen, Axsome Therapeutics, and others. Four of the other authors had no disclosures.

Source: Chiang C-C et al. Headache. 2021 Feb 5. doi: 10.1111/head.14062.

Key clinical point: Survey findings from a real-world tertiary headache clinic support the efficacy and safety of ubrogepant for acute treatment of migraine.

Major finding: Complete headache freedom and headache relief at 2 hours after taking ubrogepant for at least 75% of treated attacks were achieved in 19.0% and 47.6% of patients with migraine, respectively. Overall, 31.1% of patients reported being very satisfied with ubrogepant. Rates of adverse events were higher than those observed in clinical trials. However, no severe/serious adverse events were reported.

Study details: The data come from an analysis of questionnaire responses of 106 adult patients with migraine with or without aura treated with ubrogepant at a tertiary headache center.

Disclosures: No source of funding was declared. DW Dodick declared research support/consulting from various sources. AJ Starling declared consulting fees from Alder, Allergan, Amgen, Axsome Therapeutics, and others. Four of the other authors had no disclosures.

Source: Chiang C-C et al. Headache. 2021 Feb 5. doi: 10.1111/head.14062.

Key clinical point: Inadequate magnesium consumption through the diet is associated with migraine in US adults, aged 20-50 years.

Major finding: Only 26.1% of participants with migraine met their recommended dietary allowance (RDA) for magnesium through diet and supplements. Attainment of the RDA for magnesium through diet and supplements was associated with lower odds of migraine (adjusted odds ratio, 0.83; P = .035).

Study details: An analysis of cross-sectional data of 3,626 individuals aged 20-50 years from the National Health and Nutrition Examination Survey (2001-2004) who were categorized into migraine (n=905) and control (n=2,721) groups.

 Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Slavin M et al. Headache. 2021 Jan 27. doi: 10.1111/head.14065.

Key clinical point: Inadequate magnesium consumption through the diet is associated with migraine in US adults, aged 20-50 years.

Major finding: Only 26.1% of participants with migraine met their recommended dietary allowance (RDA) for magnesium through diet and supplements. Attainment of the RDA for magnesium through diet and supplements was associated with lower odds of migraine (adjusted odds ratio, 0.83; P = .035).

Study details: An analysis of cross-sectional data of 3,626 individuals aged 20-50 years from the National Health and Nutrition Examination Survey (2001-2004) who were categorized into migraine (n=905) and control (n=2,721) groups.

 Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Slavin M et al. Headache. 2021 Jan 27. doi: 10.1111/head.14065.

Key clinical point: Inadequate magnesium consumption through the diet is associated with migraine in US adults, aged 20-50 years.

Major finding: Only 26.1% of participants with migraine met their recommended dietary allowance (RDA) for magnesium through diet and supplements. Attainment of the RDA for magnesium through diet and supplements was associated with lower odds of migraine (adjusted odds ratio, 0.83; P = .035).

Study details: An analysis of cross-sectional data of 3,626 individuals aged 20-50 years from the National Health and Nutrition Examination Survey (2001-2004) who were categorized into migraine (n=905) and control (n=2,721) groups.

 Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Slavin M et al. Headache. 2021 Jan 27. doi: 10.1111/head.14065.

Key clinical point: Percutaneous patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder significantly reduced migraine days and attacks in patients with episodic migraine who had PFO and were refractory to preventive medical therapy.

Major finding: At 12 months, PFO closure vs. medical therapy group showed a significantly greater mean reduction in monthly migraine days (−3.1 vs. −1.9 days; P = .02) and the number of monthly migraine attacks (−2.0 vs. −1.4; P = .01). Rate of complete migraine cessation was significantly higher in PFO closure vs. medical therapy (9% vs. 0.7%; P less than .001) group. No clinically relevant adverse events were reported.

Study details: Findings are from individual patient-level data from 2 randomized migraine trials PRIMA and PREMIUM involving 337 patients with episodic migraine and PFO randomly allocated to either PFO closure+medical therapy (n=176) or medical therapy alone (n=161).

Disclosures: The study did not receive any funding. Dr. AC Charles, Dr. S Sorensen, Dr. SD Silberstein and Dr. JM Tobis were on the steering committee for the PREMIUM trial. Dr. HP Mattle and Dr. B Meier were on the steering committee for the PRIMA trial.  Dr. B West, Dr. B Meier and Dr. JM Tobis declared receiving funds, serving as proctor/speaker/consultant for various sources. All other authors declared no conflicts of interest.

Source: Mojadidi MK et al. J Am Coll Cardiol. 2021 Feb 16. doi: 10.1016/j.jacc.2020.11.068.

Key clinical point: Percutaneous patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder significantly reduced migraine days and attacks in patients with episodic migraine who had PFO and were refractory to preventive medical therapy.

Major finding: At 12 months, PFO closure vs. medical therapy group showed a significantly greater mean reduction in monthly migraine days (−3.1 vs. −1.9 days; P = .02) and the number of monthly migraine attacks (−2.0 vs. −1.4; P = .01). Rate of complete migraine cessation was significantly higher in PFO closure vs. medical therapy (9% vs. 0.7%; P less than .001) group. No clinically relevant adverse events were reported.

Study details: Findings are from individual patient-level data from 2 randomized migraine trials PRIMA and PREMIUM involving 337 patients with episodic migraine and PFO randomly allocated to either PFO closure+medical therapy (n=176) or medical therapy alone (n=161).

Disclosures: The study did not receive any funding. Dr. AC Charles, Dr. S Sorensen, Dr. SD Silberstein and Dr. JM Tobis were on the steering committee for the PREMIUM trial. Dr. HP Mattle and Dr. B Meier were on the steering committee for the PRIMA trial.  Dr. B West, Dr. B Meier and Dr. JM Tobis declared receiving funds, serving as proctor/speaker/consultant for various sources. All other authors declared no conflicts of interest.

Source: Mojadidi MK et al. J Am Coll Cardiol. 2021 Feb 16. doi: 10.1016/j.jacc.2020.11.068.

Key clinical point: Percutaneous patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder significantly reduced migraine days and attacks in patients with episodic migraine who had PFO and were refractory to preventive medical therapy.

Major finding: At 12 months, PFO closure vs. medical therapy group showed a significantly greater mean reduction in monthly migraine days (−3.1 vs. −1.9 days; P = .02) and the number of monthly migraine attacks (−2.0 vs. −1.4; P = .01). Rate of complete migraine cessation was significantly higher in PFO closure vs. medical therapy (9% vs. 0.7%; P less than .001) group. No clinically relevant adverse events were reported.

Study details: Findings are from individual patient-level data from 2 randomized migraine trials PRIMA and PREMIUM involving 337 patients with episodic migraine and PFO randomly allocated to either PFO closure+medical therapy (n=176) or medical therapy alone (n=161).

Disclosures: The study did not receive any funding. Dr. AC Charles, Dr. S Sorensen, Dr. SD Silberstein and Dr. JM Tobis were on the steering committee for the PREMIUM trial. Dr. HP Mattle and Dr. B Meier were on the steering committee for the PRIMA trial.  Dr. B West, Dr. B Meier and Dr. JM Tobis declared receiving funds, serving as proctor/speaker/consultant for various sources. All other authors declared no conflicts of interest.

Source: Mojadidi MK et al. J Am Coll Cardiol. 2021 Feb 16. doi: 10.1016/j.jacc.2020.11.068.